AcuityBio AI

AcuityBio tackles the multi-billion dollar clinical trial patient matching bottleneck using multimodal EHR reasoning. The core scientific credentials and proprietary clinical trial protocol embeddings are exceptional, but institutional investors will heavily scrutinise the lengthy 9-12 month pharma procurement sales cycle and HIPAA/data governance indemnification.

What it's building

Autonomous AI matching engine that integrates directly into hospital Electronic Health Records (EHR) to identify eligible clinical trial candidates in real-time, reducing patient screening drop-off by 70%.

For whom

Biopharma Clinical Trial Sponsors (VP of Clinical Operations) and Contract Research Organisations (CROs).

The pain

86% of clinical trials fail to meet recruitment deadlines, costing pharmaceutical companies up to $8M per day in patent expiry loss.

How it works

Zero-copy FHIR-compliant ingestion engine that queries unstructured pathology reports and genomic markers without hospital data leaving premises.

• Problem & Market Opportunity18/20
  Robust evidenceUrgent pain point with immediate CRO/sponsor budget lines already allocated.

  Fix first: Narrow SAM definition to specific Phase-II oncology rather than generic global clinical trials.

• Evidence & Traction Proof14/20
  Moderate evidenceSpeed claim is substantiated on synthetic retrospective data; prospective trial metrics are still pending.

  Fix first: Provide live cohort completion data from the ongoing Boston Medical pilot.

• Business Model & Unit Economics13/20
  Weak evidenceHybrid SaaS plus success fee creates revenue recognition complexity for pharma procurement.

  Fix first: Present pure enterprise subscription tier alongside CRO partner channel economics.

• Defensibility & Moat17/20
  Robust evidenceHospital integration pipeline and institutional IRB approval create strong defensive moats.

  Fix first: Explicitly explain data rights agreements and whether hospital trust retain exclusivity.

• Team & Execution Capability16/20
  Robust evidenceWorld-class scientific credibility that wins physician trust.

  Fix first: Designate planned use of proceeds for Senior Pharma Business Development executive.